Q: What the research shows and what to expect

<a id="evidence"</a What does the published human research on CJC-1295 actually show? The peer-reviewed human dataset is small. Early PK studies (Teichman 2006; Ionescu/Frohman 2006) in healthy adults showed single subcutaneous doses raised GH and IGF-1 for days, with a 5.8-8.1 day DAC half-life ; a 2009 proteomic study found reproducible serum changes correlating with IGF-1 . The human record is limited to these early-phase studies. Why was the CJC-1295 Phase 2 trial halted? ConjuChem's Phase 2 trial of CJC-1295 DAC in HIV-associated visceral obesity (NCT00267527) was discontinued and the DAC program did not advance . A patient death during the development era is frequently cited in connection with the halt, though a causal link to CJC-1295 was not established in the public record . What to expect when taking CJC-1295? In the published human PK studies, a single subcutaneous dose produced multi-day elevation of GH and IGF-1 while preserving the natural pulsatile pattern of GH secretion . Effects beyond these biomarker changes are not established in controlled trials, and CJC-1295 is not approved for human use — so the record describes a hormonal response, not a clinical outcome. Does CJC-1295 and ipamorelin work? GHRH analogs and GHRPs act on distinct receptors and synergize, producing GH release greater than either alone in mechanistic studies . Ipamorelin is a selective GH secretagogue ; no controlled efficacy trial of the specific CJC-1295/ipamorelin combination in healthy adults exists, so 'work' is established for the mechanism, not for any downstream outcome.

Q: Regulatory status, dosing and handling questions

<a id="regulatory"</a Is CJC-1295 FDA approved? No. CJC-1295 is not approved for human use anywhere. The 2024 FDA Pharmacy Compounding Advisory Committee reviewed it and did not recommend it for the 503A compounding bulks list, citing immunogenicity and other safety concerns. It remains a research chemical and is prohibited at all times in sport under WADA Section S2. How much CJC-1295 should I take? Human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 ug/kg . These are research doses, not a human-use recommendation; CJC-1295 is not approved for human use, and this site does not provide dosing guidance. How much CJC-1295 DAC should I take? The published DAC human PK work used 30 or 60 ug/kg subcutaneously; because of the multi-day half-life, a single dose elevated IGF-1 for 9-11 days . This is research context describing what studies administered, not dosing guidance, and CJC-1295 is unapproved for human use. How much CJC-1295 / ipamorelin should I take? There are no controlled human trials of fixed CJC-1295/ipamorelin protocols; the circulating community doses are not derived from published research . The scientific basis for pairing them is the two-receptor GHRH-plus-GHRP synergy — a mechanism, not a validated regimen. How to reconstitute CJC-1295? In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible, so studies use subcutaneous injection . This describes laboratory handling in the literature, not a preparation instruction for human use. Where to inject CJC-1295? Published studies used subcutaneous injection as the primary route, with intravenous administration in the early GRF(1-29) PK work . This describes the research route, not a human-use instruction; the compound is unapproved for human use.

Question 1

CJC-1295: definition and mechanism

Accepted Answer

This CJC-1295 FAQ is the index to every question on this site — each answered from the published record, cited where the claim is quantitative, and flagged where the record is silent. What is CJC-1295? A synthetic long-acting analog of growth-hormone-releasing hormone (GHRH), built on the hGRF(1-29) fragment with four protease-resistant substitutions; the DAC variant adds covalent serum-albumin conjugation for a multi-day half-life . The no-DAC form ('Modified GRF 1-29') keeps the four substitutions but lacks the albumin-binding moiety and is short-acting. What does CJC-1295 do? In studies it binds the pituitary GHRH receptor and stimulates pulsatile growth-hormone release, which raises hepatic IGF-1; in healthy men a single dose raised mean GH about 46% and IGF-1 about 45% one week later . The natural pulsatile pattern of GH secretion was preserved . What is CJC-1295 with DAC? The 'Drug Affinity Complex' version, in which a maleimide linker covalently binds the peptide to circulating serum albumin, extending its plasma half-life toward 5.8-8.1 days . The effective circulating species is then the much larger peptide-albumin complex , which is why one dose lasts days. What is CJC-1295 DAC? CJC-1295 DAC is the albumin-conjugated, long-acting form (half-life 5.8-8.1 days); the no-DAC 'Modified GRF 1-29' keeps the four substitutions but lacks the albumin-binding moiety and is short-acting . The two are constantly conflated but are pharmacokinetically very different — days versus minutes-to-hours. Is CJC-1295 a steroid? No. CJC-1295 is a peptide GHRH analog that acts on the pituitary GHRH receptor; it is not an anabolic-androgenic steroid and works through an entirely different mechanism . It influences the growth-hormone axis, not the androgen receptor. What is CJC-1295 ipamorelin? A research pairing of a GHRH analog (CJC-1295) with a selective GH-releasing peptide (ipamorelin); the two stimulate growth-hormone release through complementary pathways . They act on distinct receptors — the GHRH receptor versus the ghrelin/GHS receptor — which is the basis for the synergy .

Question 2

What the research shows and what to expect

Accepted Answer

<a id="evidence"</a What does the published human research on CJC-1295 actually show? The peer-reviewed human dataset is small. Early PK studies (Teichman 2006; Ionescu/Frohman 2006) in healthy adults showed single subcutaneous doses raised GH and IGF-1 for days, with a 5.8-8.1 day DAC half-life ; a 2009 proteomic study found reproducible serum changes correlating with IGF-1 . The human record is limited to these early-phase studies. Why was the CJC-1295 Phase 2 trial halted? ConjuChem's Phase 2 trial of CJC-1295 DAC in HIV-associated visceral obesity (NCT00267527) was discontinued and the DAC program did not advance . A patient death during the development era is frequently cited in connection with the halt, though a causal link to CJC-1295 was not established in the public record . What to expect when taking CJC-1295? In the published human PK studies, a single subcutaneous dose produced multi-day elevation of GH and IGF-1 while preserving the natural pulsatile pattern of GH secretion . Effects beyond these biomarker changes are not established in controlled trials, and CJC-1295 is not approved for human use — so the record describes a hormonal response, not a clinical outcome. Does CJC-1295 and ipamorelin work? GHRH analogs and GHRPs act on distinct receptors and synergize, producing GH release greater than either alone in mechanistic studies . Ipamorelin is a selective GH secretagogue ; no controlled efficacy trial of the specific CJC-1295/ipamorelin combination in healthy adults exists, so 'work' is established for the mechanism, not for any downstream outcome.

Question 3

Safety and side effects

Accepted Answer

<a id="side-effects"</a Is CJC-1295 safe? CJC-1295 is an unapproved research chemical with no large or long-term human safety trials. Theoretical concerns include fluid retention from GH-axis stimulation and the epidemiologic link between higher IGF-1 and certain cancers; the FDA cited immunogenicity concerns in 2024. Safety has not been established in any large or long-term study. Are CJC-1295 peptides safe? CJC-1295 has not been established as safe in any large or long-term human trial; it is handled as a research chemical. Known GH-axis effects such as fluid retention, and the IGF-1/cancer epidemiology, inform the theoretical risk picture, but no comprehensive human safety dataset exists . What are the side effects of CJC-1295? Reported and theoretical concerns include fluid retention and edema (GH stimulates renal sodium reabsorption), effects on insulin sensitivity, and the epidemiologic IGF-1/cancer link; FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee also flagged immunogenicity for GH secretagogues including CJC-1295. No comprehensive human safety dataset exists. Does CJC affect testosterone? CJC-1295 acts on the GH/IGF-1 axis, not directly on the gonadal axis; there is no controlled human evidence that it meaningfully raises or lowers testosterone . Most testosterone-related claims circulating online are not supported by published CJC-1295 data. Does CJC-1295 lower testosterone? There is no controlled human evidence that CJC-1295 lowers testosterone; it operates on the growth-hormone axis rather than the hypothalamic-pituitary-gonadal axis . Claims to the contrary are not grounded in published CJC-1295 studies. Are peptides safer than TRT? This comparison is not answerable from controlled head-to-head data. CJC-1295 is an unapproved research chemical with limited human safety information, whereas testosterone-replacement therapy is an approved, monitored treatment; the two act on different hormonal axes. No study compares them directly.

Question 4

Regulatory status, dosing and handling questions

Accepted Answer

<a id="regulatory"</a Is CJC-1295 FDA approved? No. CJC-1295 is not approved for human use anywhere. The 2024 FDA Pharmacy Compounding Advisory Committee reviewed it and did not recommend it for the 503A compounding bulks list, citing immunogenicity and other safety concerns. It remains a research chemical and is prohibited at all times in sport under WADA Section S2. How much CJC-1295 should I take? Human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 ug/kg . These are research doses, not a human-use recommendation; CJC-1295 is not approved for human use, and this site does not provide dosing guidance. How much CJC-1295 DAC should I take? The published DAC human PK work used 30 or 60 ug/kg subcutaneously; because of the multi-day half-life, a single dose elevated IGF-1 for 9-11 days . This is research context describing what studies administered, not dosing guidance, and CJC-1295 is unapproved for human use. How much CJC-1295 / ipamorelin should I take? There are no controlled human trials of fixed CJC-1295/ipamorelin protocols; the circulating community doses are not derived from published research . The scientific basis for pairing them is the two-receptor GHRH-plus-GHRP synergy — a mechanism, not a validated regimen. How to reconstitute CJC-1295? In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible, so studies use subcutaneous injection . This describes laboratory handling in the literature, not a preparation instruction for human use. Where to inject CJC-1295? Published studies used subcutaneous injection as the primary route, with intravenous administration in the early GRF(1-29) PK work . This describes the research route, not a human-use instruction; the compound is unapproved for human use.